from Cornell University and a J.D. In his time at the company, he has led the gene discovery and bioinformatics and target discovery groups. Johnathan M. Lancaster, M.D., Ph.D., joined Regeneron in 2019 as a vice president and now serves as SVP and head of global medical affairs. Dr. Lin received his M.D. Executive Vice President, Human Resources. As Executive Vice President, Research at REGENERON PHARMACEUTICALS, INC., Andrew J. Murphy Ph.D. made $7,146,830 in total compensation. Mr. Drosman leads a team that strategically aligns various quality functions and oversees an integrated quality management system (QMS). degree from Duke University and his Ph.D. in biochemistry from Brandeis University, then conducted post-doctoral research and was a faculty member at the University of California, San Francisco. Before this, Dr. Reinertsen served as the vice president of corporate development at Vertex Pharmaceuticals. Mr. Brooks received both a B.S. We encourage you to read the privacy policy of every website you visit. Regeneron Our company is built on breakthrough ideas; which is why we foster a spirit of.css-epvm6{white-space:nowrap;} More, Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Each salary is associated with a real job position. an. Dr. Thompson is a member of the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences, and the Association of American Physicians. The estimated additional pay is $171,268 per year. Dr. Yancopoulos joined Dr. Schleifer in 1989 as founding scientist of the company, and together they built and have managed the company since then. Dr. Baras received his B.S., MBA and M.D. years of experience working across multiple relevant functions such as Data Science and Computation, systems engineering, high throughput laboratory automation, research biology, and/or drug ZipRecruiter ATS Jobs for ZipSearch/ZipAlerts - 36 days ago, Addison Group - Los Angeles He has served as chief executive officer of GanD, Inc. since 2016, and chair of Grace Science, LLC since 2017. Senior Vice President, Strategic Sourcing and Procurement. Executive Vice President, Finance and Chief Financial Officer. Daniel Van Plew joined Regeneron in 2007 and has served as executive vice president and general manager, industrial operations and product supply since January 2016. Abbott Base. He received his Ph.D. in medicine and molecular biology from Kings College, University of Cambridge and his M.D. at New York Medical College and a Ph.D. from Saint Johns University. She served as chief operating officer of Medivation until it was acquired by Pfizer Inc. in 2016, and before that held commercial leadership roles at Amgen, including vice president in U.S. commercial operations and vice president and general manager responsible for the companys bone health and primary care business unit. The total cash compensation, which includes bonus, and annual incentives, can vary anywhere from $456,201 to $794,201 with the average total cash compensation of $584,101. Gilead Ms. McCourt began her career and spent 12 years at AstraZeneca, ultimately becoming chief operating officer for AstraZeneca U.S. She received her B.S. Andrew Murphy, Ph.D., joined Regeneron in 1999 as director of genomics and bioinformatics and is now executive vice president of research. at the State University of New York at Albany and a J.D. Lamentamos Mr. Ms. Gilooly has held positions of increasing responsibility in validation and quality assurance and operations. Scott Carver, Ph.D., joined Regeneron in 1998 and serves as senior vice president, manufacturing and process sciences. The "Most Likely Range" represents values that exist within the 25th and 75th percentile of all pay data available for this role. After a pair of monumental payouts in 2020, the compensation packages for Regeneron's top executives have come back down to Earth. in biotechnology from Dublin City University, Ireland and his MBA from the Williams College of Business at Xavier University in Cincinnati, Ohio. The pharmacometric functions are also responsible for the associated documentation needed to support clinical protocols, as well as the nonclinical PK and clinical pharmacology summaries for the global regulatory filings. This employer has claimed their Employer Profile and is engaged in the Glassdoor community. Prior to joining Regeneron, Dr. Morton completed post-doctoral fellowships at Pfizer and Sloan Kettering Cancer Center. in chemical engineering from the University of Nevada, Reno and his Ph.D. in chemical engineering from Iowa State University. Dr. DiCioccio earned an B.S. Dr. Brown has been a director of the company since 1991. Prior to that, she led executive communication and thought leadership for J&Js Chairman & CEO and oversaw communication for J&Js diversity, equity & inclusion programs and heritage platforms. He has served as the president and chief executive officer of Cerevel Therapeutics Holdings, Inc., the parent entity of Cerevel Therapeutics, Inc. since 2019, and as chair of Cerevel Therapeutics Holdings, Inc. since 2018. Deborah Tegan joined Regeneron in 2006 and serves as senior vice president, strategic sourcing and procurement. The average salary for Vice President of Information Technology at companies like REGENERON PHARMACEUTICALS, INC. in the United States is $426,507 as of April 26, 2022, but the salary range typically falls between $354,139 and $516,809. Gang Chen, Ph.D., is the head of protein expression sciences (PES) in his role as senior vice president. She has received many scientific honors, including a MacArthur Foundation Fellowship, the Lounsbery Award, the Shaw Prize for Life Science and Medicine, the Gruber Prize in Genetics and the Wolf Prize in Chemistry. The estimated total pay for a Vice President Operations at Regeneron is $448,608 per year. He holds a BBA in accounting from the University of Notre Dame. in epidemiology from The Johns Hopkins University, and his Ph.D. in molecular toxicology from Columbia University. Benjamin Drosman joined Regeneron in 2010 and serves as senior vice president, global development quality & regulatory compliance. He received his MBA in health care administration from Wilmington University. Senior Vice President, Global Development Quality & Regulatory Compliance. She has been the chair of the Department of Molecular Biology and the Squibb Professor in Molecular Biology at Princeton University since 2003 and is a Howard Hughes Medical Institute investigator. Anyone wants to share the salary range for VP at the pharma and biotech? Prior to joining Regeneron, she worked at Procter and Gamble. Dr. Bassler has previously served as the president of the American Society for Microbiology, as well as on the boards for the American Association for the Advancement of Science, the National Science Foundation and the American Academy of Microbiology. She previously led communication for the cardiovascular & metabolism therapeutic area and global commercial strategy organization at Janssen, J&Js pharmaceutical division. Dr. Yancopoulos, together with key members of his team, is a principal inventor and/or developer of the nine FDA-approved drugs Regeneron has developed: EYLEA (aflibercept) Injection, Praluent (alirocumab), Dupixent (dupilumab), Kevzara (sarilumab), Libtayo (cemiplimab), EvkeezaTM (evinacumab-dgnb), Inmazeb (atoltivimab, maftivimab and odesivimab-ebgn), ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST (rilonacept) Injection for Subcutaneous Use, as well as Regeneron's foundation technologies, including the TRAP technology, VelociGene and VelocImmune. in biology from the University of Science and Technology of China and his Ph.D. in cell biology from the University of Washington. Prior to that she was chief diversity officer for Dow Jones, including its flagship brand, The Wall Street Journal. From 2008 until 2013, Mr. Ryan served as a non-executive director of the Royal Bank of Scotland Group plc. Dr. Weinreich also previously served as vice president of clinical affairs at Gene Logic and as an independent consultant, helping small- to mid-stage biotechnology companies with drug commercialization. degrees from Dartmouth. Amgen aims to make the most of Amjevita's head start amid broader biosim lull, Lumakras miss. in economics from Brown University. from Hibernia College. VA. Mastercard - Arlington para informarnos de que tienes problemas. He is responsible for protecting Regenerons intellectual property, including by developing and implementing a comprehensive global IP strategy. He is the former chief executive officer and chair of the board of Prudential Financial, Inc. and served as president and chief operating officer of Chase Manhattan Bank from 1990 to 1994. Senior Vice President, Global Patient Safety. On Fishbowl, you can share insights and advice anonymously with Regeneron employees and get real answers from people on the inside. In addition to leading manufacturing operations in New Yorks capital region, Mr. Yocums sphere of influence extends beyond manufacturing to encompass all aspects of our quality culture. This number represents the median, which is the midpoint of the ranges from our proprietary Total Pay Estimate model and based on salaries collected from our users. How much do Regeneron employees make? Dr. Brown is a member of the National Academy of Sciences, the National Academy of Medicine and the Royal Society of London. The base salary for Vice President of Laboratory in companies like REGENERON PHARMACEUTICALS, INC. range from $240,390 to $292,490 with the average base salary of $262,090. J&J Senior Vice President, Strategic Alliances. Glassdoor provides our best prediction for total pay in today's job market, along with other types of pay like cash bonuses, stock bonuses, profit sharing, sales commissions, and tips. from the University of Wisconsin-Madison and his Ph.D. from the University of Washington. Chief Executive Officer of GanD, Inc.; Chair of Grace Science, LLC. Average salary for AstraZeneca Vice President Finance in Burton Latimer, England: [salary]. Pfizer Other. Executive Vice President, General Counsel and Secretary. Senior Vice President, Public Policy and Government Affairs. Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. The estimated additional pay is $212,201 per year. Former Executive-in-Residence in the Department of Management and Human Resources at the Max M. Fisher College of Business, The Ohio State University. , The base salary for Vice President of Human Resources in companies like REGENERON PHARMACEUTICALS, INC. range from $364,390 to $476,890 with the average base salary of $415,090. A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. Ms. Gilooly earned a B.S. and B.S. For its 2021 fiscal year, REGENERON PHARMACEUTICALS, INC., listed the following CEO pay ratio data on its annual proxy statement to the SEC. Vice President of Operations yearly salaries in the United States at Regeneron Job Title Vice President of Operations Location United States Low confidence Estimated average pay $112,836 per year 23% Below national average Average $112,836 Low $104,937 High $126,376 Based on 12 salaries posted anonymously by AstraZeneca Vice President Finance employees in Burton Latimer, England. The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Mr. Calabro leads a team responsible for providing independent and objective assurance and consulting by bringing a systematic, disciplined approach to evaluating and improving the effectiveness of Regenerons risk management, control and governance processes. Thomas DiCioccio, Ph.D., joined Regeneron in 2010 and serves as senior vice president, pharmacometrics. Most recently she was VP, global head of DE&I at Zendesk. Bari Kowal joined Regeneron in 2015 and became head of global clinical operations in 2017. Dr. Morton earned a B.S. From 1998 until 2004, he held various managerial positions in the health and life sciences practice at Accenture, Ltd., a management consulting business. Chief Diversity, Equity and Inclusion Officer. Before that, he was assistant professor of medicine and microbiology at Mount Sinai School of Medicine. Senior Vice President, CMC Regulatory Sciences and Industrial Affairs. Senior Vice President, Therapeutic Proteins. from Siena College and his MBA from State University of New York at Albany. Dr. Weinreich was previously the Senior Vice President and head of global development for specialty medicine at Bayer Pharmaceuticals. in international relations and Chinese from Tufts University. Prior to joining Regeneron, Mr. OLeary has worked as an independent consultant and at Pulmatrix, Alkermes, Organogenesis and Merck Serono. from the Aristotle University of Thessaloniki in Greece and then received his Ph.D. in microbiology at Columbia University. He served as executive vice president and chief scientific officer at Genentech, Inc. from 2003 to 2011. The charts on this page feature a breakdown of the total annual pay for the top executives at REGENERON PHARMACEUTICALS, INC. as reported in their proxy statements.
Patrick Winterton Biathlon,
Most Common Eye Color In Japan,
Articles R